首页> 外文期刊>European Journal of Haematology >A patient with a 20-year lag phase between JAK2-V617F+ myeloproliferation and NPM1-mutated AML arguing against a common origin of disease.
【24h】

A patient with a 20-year lag phase between JAK2-V617F+ myeloproliferation and NPM1-mutated AML arguing against a common origin of disease.

机译:一名患者在JAK2-V617F +骨髓增生与NPM1突变的AML之间有20年的延迟期,该患者认为是常见的疾病起源。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

We have sought to unravel the molecular biology of a female patient who in 1985 at the age of 55 was diagnosed with a chronic myeloproliferative neoplasm (MPN) and in whom overt acute myeloid leukemia (AML) developed in 2005. To this end, DNA and RNA (extracted from either paraffin-embedded bone marrow (BM) or from BM and/or peripheral blood stored in an RNA/DNA-preserving buffer) were analyzed by qPCR and by capillary gel electrophoresis of PCR products. We found the patient to be JAK2-V617F mutation positive throughout the course of disease, while a mutation of the nucleophosmin (NPM1) gene emerged at AML diagnosis and relapse. The 20-yr lag phase between the polycythemia vera and the AML adds indirect evidence to the growing realization that the leukemic transformation in patients with MPN occurs from in a JAK2 wild-type stem cell.
机译:我们试图揭示一名女性患者的分子生物学,该患者于1985年被诊断患有慢性骨髓增生性肿瘤(MPN),当时年龄55岁,该患者于2005年发生了明显的急性髓细胞性白血病(AML)。为此,DNA和通过qPCR和PCR产物的毛细管凝胶电泳分析RNA(从石蜡包埋的骨髓(BM)或从BM和/或保存在RNA / DNA保留缓冲液中的外周血中提取)。我们发现该患者在整个疾病过程中均为JAK2-V617F突变阳性,而在AML诊断和复发时出现了核磷蛋白(NPM1)基因突变。在真性红细胞增多症和AML之间存在20年的滞后阶段,这为越来越多的认识表明MPN患者的白血病转化发生在JAK2野生型干细胞中增加了间接证据。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号